The Traderszone Network

Published in TZ Latest News 27 April, 2015 by The TZ Newswire Staff

Mylan says Teva offer too low; criticizes stock, growth prospects

Teva, the world’s biggest maker of generic drugs, quickly responded to Mylan’s refusal with word that it was “fully committed” and would move forward with the $82 per share cash and stock offer. Teva said it had begun the regulatory approval process and that it expects to complete a deal by the end of 2015. The company will meet with Mylan shareholders this week, according to sources familiar with the situation.

read more